

Karyopharm's Broad Therapeutic Pipeline

AREA OF THERAPY	PRECLINICAL	PHASE I	PHASE II	PHASE III
Hematological Malignancies – Oral Selinexor				
Multiple Myeloma	BOSTON: Selinexor, Bortezomib and Dexamethasone vs. Bortezomib and Dexamethasone			
	STORM: Selinexor and Dexamethasone			
Diffuse Large B-cell Lymphoma	STOMP: Selinexor and Dexamethasone + Bortezomib, Pomalidomide, Lenalidomide or Daratumumab			
	SADAL: Selinexor			
Solid Tumors – Oral Selinexor				
Liposarcoma	SEAL: Selinexor vs. Placebo			
Gynecologic Malignancies	SIGN: Selinexor			
Glioblastoma	KING: Selinexor			
Additional Oncology Programs				
KPT-8602 Oral 2nd Generation SINE™ Compound	MM, MDS, CRC, PrC			
KPT-9274 Oral Dual PAK4/NAMPT Inhibitor	Solid Tumors & Lymphoma			
Other Indications				
Verdinexor† (KPT-335) Oral SINE™ Compound	Influenza & Other Viruses			
KPT-350 Oral SINE™ Compound	ALS, MS, DMD, TBI & Other Indications			

† Also subject to an ongoing New Animal Drug Application being submitted to FDA's Center for Veterinary Medicine, in partnership with Anivive Lifesciences, Inc. for the treatment of canine lymphoma.